Abby Reinhard

A narrative review was conducted to evaluate the relationship between gender-affirming hormone therapy and headache to advance care and improve resources for the transgender and gender-diverse population.

Lumosa Therapeutics announced that phase 2b of LT3001 met its primary safety end point, with data indicating its potential for clinical benefit.

The investigational agent NOE-105 has previously been found safe for treating adults with Tourette syndrome at 30-mg daily doses.

Developed by Wave Life Sciences, the trial of the investigational treatment, WVE-004, seeks to identify ideal dose level and frequency in patients with C9orf72-associated amyotrophic lateral sclerosis and FTD.

Jianbin Tang, data scientist and research leader from IBM Research Australia, and colleagues spoke on findings from their recent study and plans for a newly developed artificial intelligence-based model.

The phase 3 trial of pimavanserin in dementia-related psychosis, HARMONY, was previous halted due to positive efficacy signs at interim analysis. The drug is currently indicated for use in treating Parkinson disease-related psychosis.

Preliminary results showed that a fusion of accelerometry and blood volume post modalities achieved the best AUC-ROC for 9 combined seizure types.

Results and safety data from the phase 1/2 study of the therapy for Hunter syndrome/MPS II were presented at MPS 2021, the 18th International Symposium on MPS and Released Diseases, on July 25.

Investigators analyzed electronic health records from 10,095 participants over a median follow-up period of 31.7 years.

Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates a significant reduction in the probability of progressive multifocal leukoencephalopathy infection.

AC Immune, the company presenting the data at the 2021 AAIC meeting, also recently acquired an a-syn vaccine, Affiris PD01.

Phase 1b study results were presented at AAIC 2021, supporting the need for accelerated clinical development of ACI-24 in Alzheimer disease related to DS.

Participants will be enrolled for 18 months, with baseline data provided and compared to the lecanemab phase 2 study cohort.

Investigators found occurrence of DDIs through alterations in cytochrome P450 isoenzyme activity, which can be complicated by genetic polymorphism for metabolic enzymes.

Findings were consistent with recent reports from the Sleep Apnea Global Interdisciplinary Consortium; however, significant differences were identified in comparison to White participants.

Findings presented at AAIC 2021 found that long-term, daily treatment with non-invasive stimulation was both safe and well-tolerated in patients with Alzheimer disease.

Investigators evaluated the occurrence of multiple sclerosis and neuromyelitis optica spectrum disorder in Australian and New Zealand Indigenous populations, comparing data with ancestral data.

The Integrated Cognitive Assessment showed convergent validity with both MoCA and ACE and offers potential for remote measurement of cognitive performance in Alzheimer disease and mild cognitive impairment.

While rituximab treatment puts patients at a higher risk for infectious disease in general, use of such treatment poses particular risk for severe COVID-19 infections in patients with MS.

Data suggest a link between different disease-modifying strategies and the occurrence of depression when treating patients with MS.

The study data suggest that intervention strategies to improve antimicrobial and burdensome intervention for suspected LRIs and UTIs are ineffective.

Investigators found that certain underrepresented communities were less likely to be eligible for Alzheimer disease trials after the first screening visit.

The observational study, initiated by Centogene in partnership with Alector, aims to identify and explore the frequency of genetic mutations in patients with frontotemporal dementia.

The FDA breakthrough device designation follows a pilot study where patients showed a 44% median reduction in seizures when treated with Neuroelectrics’ transcranial electrical stimulation platform.

Efficacy results from a 109-week interim analysis showed improvement for patients treated with viltolarsen when compared to the matched DMD historical control group.

Research into silent myocardial infarction may help identify cause of ischemic strokes that lack etiology, as well as identify better therapeutic strategies to combat recurring stroke.

The study was conducted at Wright-Patterson Air Force Base to examine the effect of fatigue on cognition and mood within the military population.  

Analyses suggest treatment of Parkinson disease with amantadine (Gocovri; Adamas) may improve freezing and tremor, as well as other M-EDLs.

NeuroMetrix will be evaluating the effectiveness of the transcutaneous electrical nerve stimulation platform in pain relief for patients with neuromyelitis optica spectrum disorder.

The grant will fund a new study to evaluate the effectiveness of brain-responsive neuromodulation in patients with LGS. The study is expected to begin accepting patients in the second half of 2022.